(A) Upper panel: Western blot showing significant decrease (several folds) in the
Angiotensin 1/2 (2-7) of myofibroblast PKC-δ in samples treated with PKC-δ siRNA compared to control, non-specific siRNA (nsRNA) and scrambled siRNA (sRNA) (n = 3). Lower panel: Significant increase in PKC-δ expression in both AngII treated myofibroblasts (MAngII) as well as AngII infused rat hearts (HAngII) compared to control myoFb (MC) and sham hearts (HC), respectively (n = 4). (B) The PKC-δ kinase activity in both myofibroblasts and rat heart. Myofibroblasts untreated and treated with AngII, AngII and its AT1 receptor blocker losarton (AngII + AT1 blocker), AngII and PKC-δ pharmacological blocker rottlerin (AngII + Rot), AngII and its AT2 receptor blocker (AngII + PD319177), AngII its AT1 receptor specific siRNA (AngII + siRNA), PKC-δ over
expression vector (PKCd). As compared, AngII + AT1, AngII + rot, and AngII + siRNA, AngII, AngII + PD, AngII + nsRNA and PKC-δ over expression vector showed significant increase in PKC-δ kinase activity (?p
